Saturday, October 10, 2020 2:40:14 PM
Recent AKBA News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2024 08:05:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2024 08:04:58 PM
- Akebia Therapeutics to Present at the 2nd Annual HCW Bioconnect Investor Conference • PR Newswire (US) • 05/14/2024 12:00:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/13/2024 11:19:18 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/13/2024 11:17:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/09/2024 09:27:19 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 11:05:15 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 11:03:22 AM
- Akebia Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights • PR Newswire (US) • 05/09/2024 11:00:00 AM
- Akebia Therapeutics to Report First Quarter 2024 Financial Results and Discuss Recent Business Highlights • PR Newswire (US) • 05/02/2024 12:30:00 PM
- Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • PR Newswire (US) • 05/01/2024 08:05:00 PM
- Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • PR Newswire (US) • 04/02/2024 08:05:00 PM
- Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis • PR Newswire (US) • 03/28/2024 12:26:00 AM
- Akebia Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights • PR Newswire (US) • 03/14/2024 08:15:00 PM
- Akebia Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results • PR Newswire (US) • 03/11/2024 09:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/01/2024 10:49:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/01/2024 10:48:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/01/2024 10:47:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/01/2024 10:46:51 PM
- Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • PR Newswire (US) • 03/01/2024 09:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 11:03:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 11:02:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 11:01:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 11:00:49 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/29/2024 09:32:13 PM
FEATURED Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • May 17, 2024 11:00 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM
Avant Technologies to Revolutionize Data Center Management with Proprietary AI Software Platform • AVAI • May 16, 2024 8:00 AM